XML 16 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 23,786,579 $ 19,136,472
Short-term investments 103,638,844 85,629,412
Accounts receivable 6,003,205 15,821,511
Accounts receivable from affiliated entities 486,619 748,355
Prepaid expenses and other current assets 2,600,906 1,749,059
Prepaid expenses and other current assets from affiliated entities 1,846,007 1,512,424
Total current assets 138,362,160 124,597,233
Fixed assets, net 18,320,176 9,025,446
Investment in affiliated entity - GeneOne 9,069,401 16,052,065
Investment in affiliated entity - PLS 2,325,079 3,777,510
Intangible assets, net 6,009,729 7,628,394
Goodwill 10,513,371 10,513,371
Other assets 2,639,354 2,113,147
Total assets 187,239,270 173,707,166
Current liabilities:    
Accounts payable and accrued expenses 23,278,798 19,597,787
Accounts payable and accrued expenses due to affiliated entities 926,943 1,072,579
Accrued clinical trial expenses 8,611,892 6,368,389
Common stock warrants 360,795 1,167,614
Deferred revenue 1,175,353 14,762,720
Deferred revenue from affiliated entities 174,110 407,292
Deferred rent 877,535 446,646
Total current liabilities 35,405,426 43,823,027
Deferred revenue, net of current portion 215,853 317,808
Deferred revenue from affiliated entities, net of current portion 0 86,694
Deferred rent, net of current portion 9,104,416 5,926,424
Deferred tax liabilities 24,766 174,793
Total liabilities 44,750,461 50,328,746
Commitments and contingencies
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 23 at December 31, 2017 and December 31, 2016 0 0
Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2017 and December 31, 2016, issued and outstanding: 90,357,644 at December 31, 2017 and 74,062,370 at December 31, 2016 90,358 74,062
Additional paid-in capital 665,775,504 556,718,356
Accumulated deficit (523,356,317) (434,838,235)
Accumulated other comprehensive income (loss) (117,005) 1,327,968
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 142,392,540 123,282,151
Non-controlling interest 96,269 96,269
Total stockholders’ equity 142,488,809 123,378,420
Total liabilities and stockholders’ equity $ 187,239,270 $ 173,707,166